Literature DB >> 26630786

[Clinical Characteristics of Metronidazole-induced Encephalopathy: A Report of Two Cases and a Review of 32 Japanese Cases in the Literature].

Hideaki Kato, Hiroko Sosa, Masaaki Mori, Takeshi Kaneko.   

Abstract

Metronidazole is an antibiotic classically used against most anaerobic bacteria and protozoa. Because an intravenous form of metronidazole has recently entered the market, the use of this antibiotic is attracting renewed interest in many clinical settings in Japan. However, neurotoxicity is a major adverse event: in the central nervous system metronidazole-induced encephalopathy is a rare but serious condition. We performed a literature review of 34 cases including 2 of our cases, 25 from domestic conference abstracts, and 7 cases presented in full research papers. The mean patient age was 64.7 years. The conditions most commonly treated with metronidazole were brain abscess (35.3%), liver abscess (17.6%), and Clostridium difficile infection (14.7%). The most common predisposing conditions were liver dysfunction (26.5%), diabetes and other metabolic disorders (20.6%), and hematologic or solid organ malignancy (14.7%). The mean period of administration before the onset of encephalopathy symptoms was 61.3 days, and the mean total dose was 95.9g. The initial chief complaints were dysarthria (in 70.6% of the cases) and ataxia (61.8%); 82.4% of the cases were diagnosed on the basis of MRI (T2-weighted or FLAIR imaging). The key imaging finding was high intensity in the dentate nucleus bilaterally (82.4%). Stopping the metronidazole led to symptom remission within 8.5 days, but the MRI changes remained longer than the clinical symptoms. Two patients (6.0%) developed irreversible disturbance of consciousness. Although the mechanisms of this type of encephalopathy have not yet been elucidated, localized nerve-cell edema is likely caused by decreased metronidazole metabolism associated with liver and metabolic dysfunction. Careful observation for neurologic signs should be conducted during the treatment of brain abscesses associated with metronidazole administration, because patients with brain abscesses are naturally at high risk of metronidazole-induced encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26630786     DOI: 10.11150/kansenshogakuzasshi.89.559

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  7 in total

1.  Reversible metronidazole-induced neurotoxicity after 10 weeks of therapy.

Authors:  Wafa AlDhaleei; Ayesha AlMarzooqi; Nouran Gaber
Journal:  BMJ Case Rep       Date:  2018-04-20

2.  Metronidazole-associated Neurologic Events: A Nested Case-control Study.

Authors:  Nick Daneman; Yi Cheng; Tara Gomes; Jun Guan; Muhammad M Mamdani; Farah E Saxena; David N Juurlink
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

3.  Irreversible metronidazole encephalopathy in an elderly woman with primary biliary cholangitis.

Authors:  Yuki Onuma; Masayuki Oki; Masamichi Komatsu; Sho Ishitani; Kei Kijima; Ryuki Fukuda; Yusuke Moriya; Hideki Ozawa; Atsushi Takagi
Journal:  J Gen Fam Med       Date:  2017-06-21

4.  Metronidazole-induced encephalopathy associated with treatment for liver abscesses.

Authors:  Yurika Hanji; Yosuke Sasaki; Yosuke Matsumoto; Tadashi Maeda; Yoshihisa Urita
Journal:  J Gen Fam Med       Date:  2017-04-13

5.  The Occurrence of Metronidazole-Induced Encephalopathy in Cancer Patients: A Hospital-Based Retrospective Study.

Authors:  Jui-Ping Tsai; Kevin Li-Chun Hsieh; Tu-Hsueh Yeh; Yuarn-Jang Lee; Chun-Ren Wei
Journal:  Ann Indian Acad Neurol       Date:  2019 Jul-Sep       Impact factor: 1.383

6.  In Situ Reactivity of Electrochemically Generated Nitro Radical Anion on Tinidazole and Its Monomeric and Dimeric CuII Complexes on Model Biological Targets with Relative Manifestation of Preventing Bacterial Biofilm Formation.

Authors:  Promita Nandy; Ramesh C Santra; Dibyajit Lahiri; Moupriya Nag; Saurabh Das
Journal:  ACS Omega       Date:  2022-03-01

7.  Metronidazole-Associated Encephalopathy.

Authors:  Daisuke Taniyama; Taketomo Maruki
Journal:  Am J Trop Med Hyg       Date:  2018-02       Impact factor: 2.345

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.